|
 |
Diseases » Multiple Sclerosis
| Scheda |
Onset
|
20-50
years, usually during the 2nd decade of life |
| Epidemiology |
Incidence
and prevalence vary broadly throughout the world.Prevalence:
30/100000, higher in the temperate zones or northern areas of
the world. Male/female rate=0.9 |
Ethiopatogenesis
|
Acquired
immune-mediated demyelinating disease of the central nervous
system. |
| Typical
symptoms |
Visual
loss, sense dysfunction, motor dysfunction, balance and coordination
disturbances, bladder dysfunction. They can be transient or followed
by disability. |
| Clinical
course |
Relapsing-remitting,
secondary progressive, primary progressive, progressive-relapsing. |
| Therapy |
Steroid
during relapse. Immunomodulating therapies: IFNs, glatiramer.
Immunosuppressive drugs: azathioprine, cyclophosphamide, mitoxantrone,
methotrexate. |
|
|
|
|
